The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trail

被引:17
|
作者
Kasting, Monica L. [1 ]
Head, Katharine J. [2 ]
Cox, Dena [3 ]
Cox, Anthony D. [3 ]
Zimet, Gregory D. [4 ]
机构
[1] Purdue Univ, Dept Hlth & Kinesiol, 800 W Stadium Ave, W Lafayette, IN 47907 USA
[2] Indiana Univ Purdue Univ, Dept Commun Studies, 425 Univ Blvd, Indianapolis, IN 46202 USA
[3] Indiana Univ, Kelley Sch Business, 801 W Michigan St, Indianapolis, IN 46202 USA
[4] Indiana Univ, Sch Med, Dept Pediat, 410 W 10th St, Indianapolis, IN 46202 USA
关键词
Prospect theory; Hepatitis B virus; Hepatitis B vaccines; Vaccination; Vaccine uptake; Health communication; Patient acceptance of healthcare; Randomized controlled trial; Health promotion; Framing; HUMAN-PAPILLOMAVIRUS VACCINATION; LOSS-FRAMED MESSAGES; PERCEIVED RISK INFLUENCE; UNITED-STATES; RELATIVE PERSUASIVENESS; ADVISORY-COMMITTEE; HPV VACCINATION; PROSPECT-THEORY; COMMUNICATION; IMMUNIZATION;
D O I
10.1016/j.ypmed.2019.105798
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Many adults in the U.S. do not receive recommended vaccines, and the research literature remains inconclusive on the best communication strategies for increasing this behavior. This study examined the association of message framing (gained-framed vs. loss-framed vs. control), and healthcare provider (HCP) recommendation (offered vs. recommended) on uptake of adult hepatitis B virus (HBV) vaccination in a high risk population using a 3 x 2 block design randomized controlled trial. Fear of shots, fear of vaccines, and perceived message framing were examined in secondary analyses. Of the 1747 participants, 47.7% (n = 833) received 0 doses of HBV vaccine, 27.8% (n = 485) received 1 dose, 10.4% received 2 doses, and 14.1% received all 3 recommended doses. There was not a significant interaction between message framing and HCP recommendation (p = .59). Mean number of doses received by the gain-framed group (m = 0.96) was not significantly different from the loss-framed group (m = 0.97, RR = 0.99, 95% CI = 0.88-1.12). However, those receiving any framing message received significantly more doses (m = 0.96) than those in the control condition (m = 0.81, RR = 1.17, 95%CI = 1.06-1.31). Participants who received a HCP recommendation received significantly more vaccine doses (m = 0.95) than those in the vaccine-offered condition (mean = 0.82, RR = 1.16, 95%CI = 1.05-1.28). These results suggest there is no difference in vaccine uptake between gain-frame and loss-frame messages, but both are better than a control message. These results also support advising HCP to provide a strong recommendation for vaccinations beyond merely offering it to patients. This study has implications for vaccine uptake beyond HBV, and can inform future research on effective vaccine communication research.
引用
收藏
页数:8
相关论文
共 50 条
  • [42] Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial
    Pande, C.
    Sarin, S. K.
    Patra, S.
    Kumar, A.
    Mishra, S.
    Srivastava, S.
    Bhutia, K.
    Gupta, E.
    Mukhopadhyay, C. K.
    Dutta, A. K.
    Trivedi, S. S.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2013, 20 (11) : 801 - 810
  • [43] ADENINE-ARABINOSIDE MONOPHOSPHATE IN COMBINATION WITH HUMAN-LEUKOCYTE INTERFERON IN THE TREATMENT OF CHRONIC HEPATITIS-B - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRAIL
    GARCIA, G
    SMITH, CI
    WEISSBERG, JI
    EISENBERG, M
    NAIR, BJ
    KLEIN, K
    CAVARETTOJORDAN, J
    MASTRE, B
    ROSNO, S
    ROSKAMP, D
    CO, R
    WATERMAN, K
    REEVES, AK
    POLLARD, RB
    TONG, MJ
    BROWN, BW
    ROBINSON, WS
    GREGORY, PB
    MERIGAN, TC
    [J]. GASTROENTEROLOGY, 1986, 90 (05) : 1727 - 1727
  • [44] Phase 1b Randomized Controlled Trail of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy (PERIOP-04).
    Angka, Leonard
    Ivankovic, Victoria
    Mistry, Henna
    Tennakoon, Gayashan
    Tail, Lee-Hwa
    Nessim, Carolyn
    Martel, Guillaume
    Abou Khalil, Jad
    Bertens, Kimberly
    Breau, Rodney
    Dingley, Brittany
    Auer, Rebecca C.
    Auer, Rebecca C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S14 - S15
  • [45] Impact of free on-site vaccine and/or healthcare workers training on hepatitis B vaccination acceptability in high-risk subjects: a pre-post cluster randomized study
    Launay, O.
    Le Strat, Y.
    Tosini, W.
    Kara, L.
    Quelet, S.
    Levy, S.
    Danan, J.
    Reveillon, J.
    Houdayer, J.
    Bouvet, E.
    Levy-Bruhl, D.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (10) : 1033 - 1039
  • [46] EFFECTS OF INTERFERON-BETA ON NON-A, NON-B ACUTE HEPATITIS - A PROSPECTIVE, RANDOMIZED, CONTROLLED-DOSE STUDY
    TAKANO, S
    SATOMURA, Y
    OMATA, M
    YOKOSUKA, O
    OHTO, M
    OKABE, K
    IWABUCHI, S
    MUTO, Y
    MASAMUNE, K
    SATO, S
    SHINZAWA, H
    KANNO, A
    FUKUDA, Y
    HIGASHINO, K
    IORI, M
    [J]. GASTROENTEROLOGY, 1994, 107 (03) : 805 - 811
  • [47] HEPATITIS-B VACCINATION OF HEMODIALYSIS-PATIENTS - RANDOMIZED CONTROLLED TRIAL COMPARING PLASMA-DERIVED VACCINE WITH AND WITHOUT PRE-S2 ANTIGEN
    SMITLEIJS, MBL
    KRAMER, P
    HEIJTINK, RA
    HOP, WCJ
    SCHALM, SW
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (05) : 540 - 545
  • [48] Daily induction combination treatment with alfa2b interferon or standard combination treatment in naive chronic hepatitis C patients. A controlled multicenter randomized trail.
    Van Vlierberghe, HR
    Leroux-Roels, F
    Bourgeois, N
    Nevens, F
    Colie, I
    Henrion, J
    Delwaide, J
    Horsmans, Y
    Brenard, R
    Michielsen, P
    Robaeys, G
    Bruckers, L
    [J]. HEPATOLOGY, 2000, 32 (04) : 364A - 364A
  • [49] Comparison of Immunogenicity and Safety of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: A Randomized, Controlled Trial
    Chaiklang, Kanokporn
    Wipasa, Jiraprapa
    Chaiwarith, Romanee
    Praparattanapan, Jutarat
    Supparatpinyo, Khuanchai
    [J]. PLOS ONE, 2013, 8 (11):
  • [50] A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis
    Hung, Ivan Fan-Ngai
    Yap, Desmond Yat-Hin
    Yip, Terence Pok-Siu
    Zhang, Ricky Ruiqi
    To, Kelvin Kai-Wang
    Chan, Kwok-Hung
    Tang, Sydney Chi-Wai
    Lui, Sing-Leung
    Levin, Yotam
    Kochba, Efrat
    Lau, Johnson Yiu-Nam
    Yuen, Man-Fung
    Chan, Tak-Mao
    Yuen, Kwok-Yung
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (02) : E304 - E311